Life Science Leader - thought leadership articles and discussions about the current life science industry

Dec 11, 2024 · By Arda Ural, Ph.D. Arda Ural, Ph.D. Key innovation, technology, dealmaking and policy considerations are reshaping the industry’s future. While patent expirations of $300b will continue to put pressure on growth, robust innovation likely will partially offset top-line erosion.

Oct 3, 2024 · <p>An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment and return. However, it won&#39;t work for every company, as Abbas Kazimi, chief business officer at Nimbus Therapeutics, explains.</p>

Oct 18, 2024 · By Ben Comer, Chief Editor, Life Science Leader. Stella Sarraf, Ph.D. Using small molecule drugs to restore synapses in neurological diseases. Snapshot. Los Angeles-based Spinogenix, a privately held small molecule drug discovery and development company, is currently testing two clinical candidates in four diseases: SPG302 in amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and ...

May 1, 2024 · By Ben Comer, Chief Editor, Life Science Leader. Armon Sharei. Then: In the March 2019 issue of Life Science Leader, SQZ Biotech cofounder and CEO Armon Sharei, Ph.D., reflected on his initial attraction to an MIT project led by Professor Klavs Jensen: delivering materials into cells using a microfluidic gun. “Imagine a miniaturized, high-powered squirt gun designed to fire things into cells ...

Jan 8, 2025 · The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing number of government initiatives behind it, more investment from both public and private sectors being ...

Sep 27, 2024 · By Ben Comer, Chief Editor, Life Science Leader. Alicia Zhou, Ph.D. Dr. Alicia Zhou, Ph.D., the new CEO at the Cancer Research Institute (CRI), aims to bring her experience in academia and the West Coast health tech startup scene to bear on a 70-year-old nonprofit institution with deep roots in cancer immunotherapy.

Jan 29, 2025 · With 23,000 drug candidates currently in development, biopharmaceutical companies are operating at unprecedented levels of R&D activity. 2025 is shaping up to be another strong year for pipeline growth, but difficulties lie ahead as the industry approaches the largest patent cliff in history, in addition to rising drug development costs and timelines adding immense strain on budgets.

Dec 19, 2024 · <p>Local market pharmacovigilance (PV) requirements can be daunting to manage successfully. Experts at PharmaLex provide best practices for managing PV across local affiliates.</p>

Sep 22, 2024 · By Ben Comer, Chief Editor, Life Science Leader. Steven Kelly. Then: In a 2021 “Companies To Watch” article written by Wayne Koberstein, Carisma Therapeutics CEO Steven Kelly spoke about his three-pronged mandate to fund the (then) privately held company, build a team, and define a purpose. “Our purpose was to translate the discoveries made [by Michael Klichinsky and Saar Gill] at the ...